TY - STD TI - Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2020. ID - ref1 ER - TY - JOUR AU - Yang, J. AU - Hainaut, P. AU - Gores, G. AU - Amadou, A. AU - Plymoth, A. AU - Roberts, L. PY - 2019 DA - 2019// TI - A global view of hepatocellular carcinoma: trends, risk, prevention and management JO - Nat Rev Gastroenterol Hepatol VL - 16 UR - https://doi.org/10.1038/s41575-019-0186-y DO - 10.1038/s41575-019-0186-y ID - Yang2019 ER - TY - JOUR AU - Siegel, R. AU - Miller, K. AU - Jemal, A. PY - 2020 DA - 2020// TI - Cancer statistics, 2020 JO - CA Cancer J Clin VL - 70 UR - https://doi.org/10.3322/caac.21590 DO - 10.3322/caac.21590 ID - Siegel2020 ER - TY - JOUR AU - Lan, A. AU - Hongmei, Z. AU - Zheng, R. AU - Xi, Z. AU - Kexin, S. AU - Xiaonong, Z. PY - 2019 DA - 2019// TI - Analysis of the prevalence of liver cancer in China in 2015 JO - Chin J Oncol VL - 41 ID - Lan2019 ER - TY - JOUR AU - Forner, A. AU - Llovet, J. AU - Bruix, J. PY - 2012 DA - 2012// TI - Hepatocellular carcinoma JO - Lancet (London, England) VL - 379 UR - https://doi.org/10.1016/S0140-6736(11)61347-0 DO - 10.1016/S0140-6736(11)61347-0 ID - Forner2012 ER - TY - JOUR AU - Zhou, W. AU - Zhang, Q. AU - Qiao, L. PY - 2014 DA - 2014// TI - Pathogenesis of liver cirrhosis JO - World J Gastroenterol VL - 20 UR - https://doi.org/10.3748/wjg.v20.i23.7312 DO - 10.3748/wjg.v20.i23.7312 ID - Zhou2014 ER - TY - JOUR AU - Rao, H. AU - Wu, E. AU - Fu, S. AU - Yang, M. AU - Feng, B. AU - Lin, A. PY - 2017 DA - 2017// TI - The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease JO - Aliment Pharmacol Ther VL - 46 UR - https://doi.org/10.1111/apt.14273 DO - 10.1111/apt.14273 ID - Rao2017 ER - TY - JOUR AU - Schulze, K. AU - Imbeaud, S. AU - Letouzé, E. AU - Alexandrov, L. AU - Calderaro, J. AU - Rebouissou, S. PY - 2015 DA - 2015// TI - Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets JO - Nat Genet VL - 47 UR - https://doi.org/10.1038/ng.3252 DO - 10.1038/ng.3252 ID - Schulze2015 ER - TY - JOUR AU - Balkwill, F. AU - Mantovani, A. PY - 2001 DA - 2001// TI - Inflammation and cancer: back to Virchow? JO - Lancet (London, England) VL - 357 UR - https://doi.org/10.1016/S0140-6736(00)04046-0 DO - 10.1016/S0140-6736(00)04046-0 ID - Balkwill2001 ER - TY - JOUR AU - Duan, Q. AU - Zhang, H. AU - Zheng, J. AU - Zhang, L. PY - 2020 DA - 2020// TI - Turning cold into hot: firing up the tumor microenvironment JO - Trends Cancer VL - 6 UR - https://doi.org/10.1016/j.trecan.2020.02.022 DO - 10.1016/j.trecan.2020.02.022 ID - Duan2020 ER - TY - JOUR AU - Kurebayashi, Y. AU - Ojima, H. AU - Tsujikawa, H. AU - Kubota, N. AU - Maehara, J. AU - Abe, Y. PY - 2018 DA - 2018// TI - Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification JO - Hepatology (Baltimore, Md) VL - 68 UR - https://doi.org/10.1002/hep.29904 DO - 10.1002/hep.29904 ID - Kurebayashi2018 ER - TY - JOUR AU - Binnewies, M. AU - Roberts, E. AU - Kersten, K. AU - Chan, V. AU - Fearon, D. AU - Merad, M. PY - 2018 DA - 2018// TI - Understanding the tumor immune microenvironment (TIME) for effective therapy JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0014-x DO - 10.1038/s41591-018-0014-x ID - Binnewies2018 ER - TY - JOUR AU - Couri, T. AU - Pillai, A. PY - 2019 DA - 2019// TI - Goals and targets for personalized therapy for HCC JO - Hepatol Int VL - 13 UR - https://doi.org/10.1007/s12072-018-9919-1 DO - 10.1007/s12072-018-9919-1 ID - Couri2019 ER - TY - JOUR AU - Lee, S. AU - Kang, T. AU - Cha, D. AU - Song, K. AU - Lee, M. AU - Rhim, H. PY - 2018 DA - 2018// TI - Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: propensity score analyses of long-term outcomes JO - J Hepatol VL - 69 UR - https://doi.org/10.1016/j.jhep.2018.02.026 DO - 10.1016/j.jhep.2018.02.026 ID - Lee2018 ER - TY - JOUR AU - Cheng, A. AU - Kang, Y. AU - Chen, Z. AU - Tsao, C. AU - Qin, S. AU - Kim, J. PY - 2009 DA - 2009// TI - Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70285-7 DO - 10.1016/S1470-2045(08)70285-7 ID - Cheng2009 ER - TY - JOUR AU - Llovet, J. M. AU - Ricci, S. AU - Mazzaferro, V. AU - Hilgard, P. AU - Gane, E. AU - Blanc, J. F. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - JOUR AU - Finn, R. AU - Qin, S. AU - Ikeda, M. AU - Galle, P. AU - Ducreux, M. AU - Kim, T. PY - 2020 DA - 2020// TI - Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMoa1915745 DO - 10.1056/NEJMoa1915745 ID - Finn2020 ER - TY - JOUR AU - Kelley, R. PY - 2020 DA - 2020// TI - Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer JO - N Engl J Med VL - 382 UR - https://doi.org/10.1056/NEJMe2004851 DO - 10.1056/NEJMe2004851 ID - Kelley2020 ER - TY - JOUR AU - Han, S. AU - Zhen, W. AU - Guo, T. AU - Zou, J. AU - Li, F. PY - 2020 DA - 2020// TI - SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway JO - J Exp Clin Cancer Res VL - 39 UR - https://doi.org/10.1186/s13046-020-01730-8 DO - 10.1186/s13046-020-01730-8 ID - Han2020 ER - TY - JOUR AU - Calderaro, J. AU - Ziol, M. AU - Paradis, V. AU - Zucman-Rossi, J. PY - 2019 DA - 2019// TI - Molecular and histological correlations in liver cancer JO - J Hepatol VL - 71 UR - https://doi.org/10.1016/j.jhep.2019.06.001 DO - 10.1016/j.jhep.2019.06.001 ID - Calderaro2019 ER - TY - STD TI - Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169(7):1342–1356.e16. ID - ref21 ER - TY - JOUR AU - Calderaro, J. AU - Couchy, G. AU - Imbeaud, S. AU - Amaddeo, G. AU - Letouzé, E. AU - Blanc, J. PY - 2017 DA - 2017// TI - Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification JO - J Hepatol VL - 67 UR - https://doi.org/10.1016/j.jhep.2017.05.014 DO - 10.1016/j.jhep.2017.05.014 ID - Calderaro2017 ER - TY - JOUR AU - Sia, D. AU - Jiao, Y. AU - Martinez-Quetglas, I. AU - Kuchuk, O. AU - Villacorta-Martin, C. PY - 2017 DA - 2017// TI - Castro de Moura M, et al. identification of an immune-specific class of hepatocellular carcinoma, based on molecular features JO - Gastroenterology. VL - 153 UR - https://doi.org/10.1053/j.gastro.2017.06.007 DO - 10.1053/j.gastro.2017.06.007 ID - Sia2017 ER - TY - JOUR AU - Salomao, M. AU - Yu, W. AU - Brown, R. AU - Emond, J. AU - Lefkowitch, J. PY - 2010 DA - 2010// TI - Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH JO - Am J Surg Pathol VL - 34 UR - https://doi.org/10.1097/PAS.0b013e3181f31caa DO - 10.1097/PAS.0b013e3181f31caa ID - Salomao2010 ER - TY - JOUR AU - Chan, A. AU - Tong, J. AU - Pan, Y. AU - Chan, S. AU - Wong, G. AU - Wong, V. PY - 2015 DA - 2015// TI - Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome JO - Am J Surg Pathol VL - 39 UR - https://doi.org/10.1097/PAS.0000000000000376 DO - 10.1097/PAS.0000000000000376 ID - Chan2015 ER - TY - JOUR AU - Nakagawa, S. AU - Umezaki, N. AU - Yamao, T. AU - Kaida, T. AU - Okabe, H. AU - Mima, K. PY - 2018 DA - 2018// TI - Survival impact of lymphocyte infiltration into the tumor of hepatocellular carcinoma in hepatitis B virus-positive or non-B non-C patients who underwent curative resection JO - Hepatol Res VL - 48 UR - https://doi.org/10.1111/hepr.12936 DO - 10.1111/hepr.12936 ID - Nakagawa2018 ER - TY - JOUR AU - Calderaro, J. AU - Petitprez, F. AU - Becht, E. AU - Laurent, A. AU - Hirsch, T. AU - Rousseau, B. PY - 2019 DA - 2019// TI - Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma JO - J Hepatol VL - 70 UR - https://doi.org/10.1016/j.jhep.2018.09.003 DO - 10.1016/j.jhep.2018.09.003 ID - Calderaro2019 ER - TY - JOUR AU - Llovet, J. AU - Montal, R. AU - Sia, D. AU - Finn, R. PY - 2018 DA - 2018// TI - Molecular therapies and precision medicine for hepatocellular carcinoma JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/s41571-018-0073-4 DO - 10.1038/s41571-018-0073-4 ID - Llovet2018 ER - TY - JOUR AU - Shimada, S. AU - Mogushi, K. AU - Akiyama, Y. AU - Furuyama, T. AU - Watanabe, S. AU - Ogura, T. PY - 2019 DA - 2019// TI - Comprehensive molecular and immunological characterization of hepatocellular carcinoma JO - EBioMedicine. VL - 40 UR - https://doi.org/10.1016/j.ebiom.2018.12.058 DO - 10.1016/j.ebiom.2018.12.058 ID - Shimada2019 ER - TY - JOUR AU - Tsujikawa, H. AU - Masugi, Y. AU - Yamazaki, K. AU - Itano, O. AU - Kitagawa, Y. AU - Sakamoto, M. PY - 2016 DA - 2016// TI - Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness JO - Hum Pathol VL - 50 UR - https://doi.org/10.1016/j.humpath.2015.10.014 DO - 10.1016/j.humpath.2015.10.014 ID - Tsujikawa2016 ER - TY - JOUR AU - Uenishi, T. AU - Kubo, S. AU - Yamamoto, T. AU - Shuto, T. AU - Ogawa, M. AU - Tanaka, H. PY - 2003 DA - 2003// TI - Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence JO - Cancer Sci VL - 94 UR - https://doi.org/10.1111/j.1349-7006.2003.tb01366.x DO - 10.1111/j.1349-7006.2003.tb01366.x ID - Uenishi2003 ER - TY - JOUR AU - Sakamoto, M. AU - Effendi, K. AU - Masugi, Y. PY - 2010 DA - 2010// TI - Molecular diagnosis of multistage hepatocarcinogenesis JO - Jpn J Clin Oncol VL - 40 UR - https://doi.org/10.1093/jjco/hyq099 DO - 10.1093/jjco/hyq099 ID - Sakamoto2010 ER - TY - STD TI - Meylan M, Petitprez F, Lacroix L, Di Tommaso L, Roncalli M, Bougoüin A, et al. Early hepatic lesions display immature tertiary lymphoid structures and show elevated expression of immune inhibitory and immunosuppressive molecules. Clin Cancer Res. 2020. ID - ref33 ER - TY - JOUR AU - Greten, T. AU - Duffy, A. AU - Korangy, F. PY - 2013 DA - 2013// TI - Hepatocellular carcinoma from an immunologic perspective JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1721 DO - 10.1158/1078-0432.CCR-13-1721 ID - Greten2013 ER - TY - JOUR AU - Robinson, M. AU - Harmon, C. AU - O'Farrelly, C. PY - 2016 DA - 2016// TI - Liver immunology and its role in inflammation and homeostasis JO - Cell Mol Immunol VL - 13 UR - https://doi.org/10.1038/cmi.2016.3 DO - 10.1038/cmi.2016.3 ID - Robinson2016 ER - TY - JOUR AU - Flecken, T. AU - Schmidt, N. AU - Hild, S. AU - Gostick, E. AU - Drognitz, O. AU - Zeiser, R. PY - 2014 DA - 2014// TI - Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma JO - Hepatology (Baltimore, Md) VL - 59 UR - https://doi.org/10.1002/hep.26731 DO - 10.1002/hep.26731 ID - Flecken2014 ER - TY - JOUR AU - Guidotti, L. AU - Inverso, D. AU - Sironi, L. AU - Lucia, P. AU - Fioravanti, J. AU - Ganzer, L. PY - 2015 DA - 2015// TI - Immunosurveillance of the liver by intravascular effector CD8(+) T cells JO - Cell. VL - 161 UR - https://doi.org/10.1016/j.cell.2015.03.005 DO - 10.1016/j.cell.2015.03.005 ID - Guidotti2015 ER - TY - JOUR AU - Garnelo, M. AU - Tan, A. AU - Her, Z. AU - Yeong, J. AU - Lim, C. AU - Chen, J. PY - 2017 DA - 2017// TI - Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma JO - Gut. VL - 66 UR - https://doi.org/10.1136/gutjnl-2015-310814 DO - 10.1136/gutjnl-2015-310814 ID - Garnelo2017 ER - TY - JOUR AU - Ma, C. AU - Kesarwala, A. AU - Eggert, T. AU - Medina-Echeverz, J. AU - Kleiner, D. AU - Jin, P. PY - 2016 DA - 2016// TI - NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis JO - Nature. VL - 531 UR - https://doi.org/10.1038/nature16969 DO - 10.1038/nature16969 ID - Ma2016 ER - TY - STD TI - Spranger S, Dai D, Horton B, Gajewski T. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017;31(5):711–723.e4. ID - ref40 ER - TY - JOUR AU - Doherty, D. PY - 2016 DA - 2016// TI - Immunity, tolerance and autoimmunity in the liver: a comprehensive review JO - J Autoimmun VL - 66 UR - https://doi.org/10.1016/j.jaut.2015.08.020 DO - 10.1016/j.jaut.2015.08.020 ID - Doherty2016 ER - TY - STD TI - Zhang Q, He Y, Luo N, Patel S, Han Y, Gao R, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019;179(4):829–845.e20. ID - ref42 ER - TY - JOUR AU - Chew, V. AU - Lai, L. AU - Pan, L. AU - Lim, C. AU - Li, J. AU - Ong, R. PY - 2017 DA - 2017// TI - Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses JO - Proc Natl Acad Sci U S A VL - 114 UR - https://doi.org/10.1073/pnas.1706559114 DO - 10.1073/pnas.1706559114 ID - Chew2017 ER - TY - JOUR AU - Yan, W. AU - Liu, X. AU - Ma, H. AU - Zhang, H. AU - Song, X. AU - Gao, L. PY - 2015 DA - 2015// TI - Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages JO - Gut. VL - 64 UR - https://doi.org/10.1136/gutjnl-2014-307671 DO - 10.1136/gutjnl-2014-307671 ID - Yan2015 ER - TY - STD TI - J Wu, W Gao, Q Tang, Y Yu, W You, Z Wu, et al. M2 macrophage-derived exosomes facilitate hepatocarcinoma metastasis by transferring α β integrin to tumor cells. Hepatology (Baltimore, Md). 2020. ID - ref45 ER - TY - STD TI - G Liu, X Ouyang, Y Sun, Y Xiao, B You, Y Gao, et al. The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR/PHLPP/p-AKT/β-catenin signaling. Cell death and differentiation. 2020. ID - ref46 ER - TY - JOUR AU - Topalian, S. PY - 2017 DA - 2017// TI - Targeting immune checkpoints in Cancer therapy JO - JAMA. VL - 318 UR - https://doi.org/10.1001/jama.2017.14155 DO - 10.1001/jama.2017.14155 ID - Topalian2017 ER - TY - JOUR AU - He, X. AU - Xu, C. PY - 2020 DA - 2020// TI - Immune checkpoint signaling and cancer immunotherapy JO - Cell Res VL - 30 UR - https://doi.org/10.1038/s41422-020-0343-4 DO - 10.1038/s41422-020-0343-4 ID - He2020 ER - TY - JOUR AU - Fallah-Mehrjardi, K. AU - Mirzaei, H. AU - Masoumi, E. AU - Jafarzadeh, L. AU - Rostamian, H. AU - Khakpoor-Koosheh, M. PY - 2020 DA - 2020// TI - Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro JO - Immunol Lett VL - 223 UR - https://doi.org/10.1016/j.imlet.2020.04.005 DO - 10.1016/j.imlet.2020.04.005 ID - Fallah-Mehrjardi2020 ER - TY - JOUR AU - Liu, F. AU - Liu, Y. AU - Chen, Z. PY - 2018 DA - 2018// TI - Tim-3 expression and its role in hepatocellular carcinoma JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0667-4 DO - 10.1186/s13045-018-0667-4 ID - Liu2018 ER - TY - JOUR AU - Angelova, M. AU - Charoentong, P. AU - Hackl, H. AU - Fischer, M. AU - Snajder, R. AU - Krogsdam, A. PY - 2015 DA - 2015// TI - Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy JO - Genome Biol VL - 16 UR - https://doi.org/10.1186/s13059-015-0620-6 DO - 10.1186/s13059-015-0620-6 ID - Angelova2015 ER - TY - JOUR AU - Gatalica, Z. AU - Snyder, C. AU - Maney, T. AU - Ghazalpour, A. AU - Holterman, D. AU - Xiao, N. PY - 2014 DA - 2014// TI - Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type JO - Cancer #pidemiol, Biomark Prevent VL - 23 UR - https://doi.org/10.1158/1055-9965.EPI-14-0654 DO - 10.1158/1055-9965.EPI-14-0654 ID - Gatalica2014 ER - TY - JOUR AU - Brown, Z. AU - Yu, S. AU - Heinrich, B. AU - Ma, C. AU - Fu, Q. AU - Sandhu, M. PY - 2018 DA - 2018// TI - Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma JO - Cancer Immunol Immunother CII VL - 67 UR - https://doi.org/10.1007/s00262-018-2190-4 DO - 10.1007/s00262-018-2190-4 ID - Brown2018 ER - TY - STD TI - Leach D, Krummel M, Allison J. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY). 1996;271(5256):1734–6. ID - ref54 ER - TY - JOUR AU - Melero, I. AU - Hervas-Stubbs, S. AU - Glennie, M. AU - Pardoll, D. AU - Chen, L. PY - 2007 DA - 2007// TI - Immunostimulatory monoclonal antibodies for cancer therapy JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2051 DO - 10.1038/nrc2051 ID - Melero2007 ER - TY - STD TI - El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England, 2017;389(10088):2492–502. ID - ref56 ER - TY - JOUR AU - Finkelmeier, F. AU - Waidmann, O. AU - Trojan, J. PY - 2018 DA - 2018// TI - Nivolumab for the treatment of hepatocellular carcinoma JO - Expert Rev Anticancer Ther VL - 18 UR - https://doi.org/10.1080/14737140.2018.1535315 DO - 10.1080/14737140.2018.1535315 ID - Finkelmeier2018 ER - TY - JOUR AU - Finkelmeier, F. AU - Czauderna, C. AU - Perkhofer, L. AU - Ettrich, T. AU - Trojan, J. AU - Weinmann, A. PY - 2019 DA - 2019// TI - Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers JO - J Cancer Res Clin Oncol VL - 145 UR - https://doi.org/10.1007/s00432-018-2780-8 DO - 10.1007/s00432-018-2780-8 ID - Finkelmeier2019 ER - TY - STD TI - Zhou G, Sprengers D, Boor P, Doukas M, Schutz H, Mancham S, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology. 2017;153(4):1107–1119.e10. ID - ref59 ER - TY - JOUR AU - Zhou, Q. AU - Munger, M. AU - Veenstra, R. AU - Weigel, B. AU - Hirashima, M. AU - Munn, D. PY - 2011 DA - 2011// TI - Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia JO - Blood. VL - 117 UR - https://doi.org/10.1182/blood-2010-10-310425 DO - 10.1182/blood-2010-10-310425 ID - Zhou2011 ER - TY - JOUR AU - Li, J. AU - Shayan, G. AU - Avery, L. AU - Jie, H. AU - Gildener-Leapman, N. AU - Schmitt, N. PY - 2016 DA - 2016// TI - Tumor-infiltrating Tim-3 T cells proliferate avidly except when PD-1 is co-expressed: evidence for intracellular cross talk JO - Oncoimmunology. VL - 5 UR - https://doi.org/10.1080/2162402X.2016.1200778 DO - 10.1080/2162402X.2016.1200778 ID - Li2016 ER - TY - JOUR AU - Sakuishi, K. AU - Apetoh, L. AU - Sullivan, J. AU - Blazar, B. AU - Kuchroo, V. AU - Anderson, A. PY - 2010 DA - 2010// TI - Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity JO - J Exp Med VL - 207 UR - https://doi.org/10.1084/jem.20100643 DO - 10.1084/jem.20100643 ID - Sakuishi2010 ER - TY - JOUR AU - Koyama, S. AU - Akbay, E. AU - Li, Y. AU - Herter-Sprie, G. AU - Buczkowski, K. AU - Richards, W. PY - 2016 DA - 2016// TI - Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10501 DO - 10.1038/ncomms10501 ID - Koyama2016 ER - TY - JOUR AU - Ngiow, S. AU - Scheidt, B. AU - Akiba, H. AU - Yagita, H. AU - Teng, M. AU - Smyth, M. PY - 2011 DA - 2011// TI - Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-0096 DO - 10.1158/0008-5472.CAN-11-0096 ID - Ngiow2011 ER - TY - JOUR AU - Guo, Z. AU - Cheng, D. AU - Xia, Z. AU - Luan, M. AU - Wu, L. AU - Wang, G. PY - 2013 DA - 2013// TI - Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer JO - J Transl Med VL - 11 UR - https://doi.org/10.1186/1479-5876-11-215 DO - 10.1186/1479-5876-11-215 ID - Guo2013 ER - TY - JOUR AU - Kim, J. AU - Patel, M. AU - Mangraviti, A. AU - Kim, E. AU - Theodros, D. AU - Velarde, E. PY - 2017 DA - 2017// TI - Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine Gliomas JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-15-1535 DO - 10.1158/1078-0432.CCR-15-1535 ID - Kim2017 ER - TY - JOUR AU - Kang, C. AU - Dutta, A. AU - Chang, L. AU - Mahalingam, J. AU - Lin, Y. AU - Chiang, J. PY - 2015 DA - 2015// TI - Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer JO - Sci Rep VL - 5 UR - https://doi.org/10.1038/srep15659 DO - 10.1038/srep15659 ID - Kang2015 ER - TY - JOUR AU - Liu, F. AU - Zeng, G. AU - Zhou, S. AU - He, X. AU - Sun, N. AU - Zhu, X. PY - 2018 DA - 2018// TI - Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma JO - Bull Cancer VL - 105 UR - https://doi.org/10.1016/j.bulcan.2018.01.018 DO - 10.1016/j.bulcan.2018.01.018 ID - Liu2018 ER - TY - JOUR AU - Omar, H. A. AU - E-Serafi, A. T. AU - Hersi, F. AU - Arafa, E. A. AU - Zaher, D. M. AU - Madkour, M. PY - 2019 DA - 2019// TI - Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment JO - FEBS J VL - 286 UR - https://doi.org/10.1111/febs.15000 DO - 10.1111/febs.15000 ID - Omar2019 ER - TY - JOUR AU - Guo, W. AU - Tan, W. AU - Liu, S. AU - Huang, X. AU - Lin, J. AU - Liang, R. PY - 2015 DA - 2015// TI - MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma JO - Tumour Biol VL - 36 UR - https://doi.org/10.1007/s13277-015-3644-3 DO - 10.1007/s13277-015-3644-3 ID - Guo2015 ER - TY - JOUR AU - Lin, Y. AU - Liu, S. AU - Su, L. AU - Su, Q. AU - Lin, J. AU - Huang, X. PY - 2018 DA - 2018// TI - miR-570 inhibits proliferation, angiogenesis, and immune escape of hepatocellular carcinoma JO - Cancer Biother Radiopharm VL - 33 ID - Lin2018 ER - TY - JOUR AU - Zhu, J. AU - Chen, L. AU - Zou, L. AU - Yang, P. AU - Wu, R. AU - Mao, Y. PY - 2014 DA - 2014// TI - MiR-20b, −21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer JO - Hum Immunol VL - 75 UR - https://doi.org/10.1016/j.humimm.2014.01.006 DO - 10.1016/j.humimm.2014.01.006 ID - Zhu2014 ER - TY - JOUR AU - Xi, J. AU - Huang, Q. AU - Wang, L. AU - Ma, X. AU - Deng, Q. AU - Kumar, M. PY - 2018 DA - 2018// TI - miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy JO - Oncogene. VL - 37 UR - https://doi.org/10.1038/s41388-018-0178-3 DO - 10.1038/s41388-018-0178-3 ID - Xi2018 ER - TY - JOUR AU - Li, B. AU - Lu, Y. AU - Yu, L. AU - Han, X. AU - Wang, H. AU - Mao, J. PY - 2017 DA - 2017// TI - miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation JO - Chem-Biol Interact VL - 277 UR - https://doi.org/10.1016/j.cbi.2017.08.014 DO - 10.1016/j.cbi.2017.08.014 ID - Li2017 ER - TY - JOUR AU - Ma, S. AU - Liu, M. AU - Xu, Z. AU - Li, Y. AU - Guo, H. AU - Ge, Y. PY - 2016 DA - 2016// TI - A double feedback loop mediated by microRNA-23a/27a/24-2 regulates M1 versus M2 macrophage polarization and thus regulates cancer progression JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.6284 DO - 10.18632/oncotarget.6284 ID - Ma2016 ER - TY - STD TI - Cortez M, Ivan C, Valdecanas D, Wang X, Peltier H, Ye Y, et al. PDL1 Regulation by p53 via miR-34. Journal of the National Cancer Institute. 2016;108(1). ID - ref76 ER - TY - JOUR AU - Zonari, E. AU - Pucci, F. AU - Saini, M. AU - Mazzieri, R. AU - Politi, L. AU - Gentner, B. PY - 2013 DA - 2013// TI - A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2012-08-449306 DO - 10.1182/blood-2012-08-449306 ID - Zonari2013 ER - TY - JOUR AU - Komohara, Y. AU - Fujiwara, Y. AU - Ohnishi, K. AU - Takeya, M. PY - 2016 DA - 2016// TI - Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy JO - Adv Drug Deliv Rev VL - 99 UR - https://doi.org/10.1016/j.addr.2015.11.009 DO - 10.1016/j.addr.2015.11.009 ID - Komohara2016 ER - TY - STD TI - Wang L, Hu Y, Zhao J, Huang F, Liang S, Dong L, et al. Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression. Journal for immunotherapy of cancer. 2020;8(2). ID - ref79 ER - TY - STD TI - Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, et al. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. 2018;154(4):1024–1036.e9. ID - ref80 ER - TY - JOUR AU - Xu, G. AU - Feng, D. AU - Yao, Y. AU - Li, P. AU - Sun, H. AU - Yang, H. PY - 2020 DA - 2020// TI - Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization JO - Oncogene. VL - 39 UR - https://doi.org/10.1038/s41388-019-1072-3 DO - 10.1038/s41388-019-1072-3 ID - Xu2020 ER - TY - JOUR AU - Shigeta, K. AU - Datta, M. AU - Hato, T. AU - Kitahara, S. AU - Chen, I. X. AU - Matsui, A. PY - 2020 DA - 2020// TI - Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma JO - Hepatology. VL - 71 UR - https://doi.org/10.1002/hep.30889 DO - 10.1002/hep.30889 ID - Shigeta2020 ER - TY - JOUR AU - Zhou, B. AU - Li, C. AU - Yang, Y. AU - Wang, Z. PY - 2020 DA - 2020// TI - RIG-I promotes cell death in hepatocellular carcinoma by inducing M1 polarization of Perineal macrophages through the RIG-I/MAVS/NF-κB pathway JO - OncoTargets Ther VL - 13 UR - https://doi.org/10.2147/OTT.S258450 DO - 10.2147/OTT.S258450 ID - Zhou2020 ER - TY - JOUR AU - Zhou, B. AU - Yang, Y. AU - Li, C. PY - 2019 DA - 2019// TI - SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway JO - OncoTargets Ther VL - 12 UR - https://doi.org/10.2147/OTT.S195234 DO - 10.2147/OTT.S195234 ID - Zhou2019 ER - TY - JOUR AU - Zhang, Z. AU - Zhang, J. AU - He, P. AU - Han, J. AU - Sun, C. PY - 2020 DA - 2020// TI - Interleukin-37 suppresses hepatocellular carcinoma growth through inhibiting M2 polarization of tumor-associated macrophages JO - Mol Immunol VL - 122 UR - https://doi.org/10.1016/j.molimm.2020.03.012 DO - 10.1016/j.molimm.2020.03.012 ID - Zhang2020 ER - TY - JOUR AU - Li, L. AU - Sun, P. AU - Zhang, C. AU - Li, Z. AU - Cui, K. AU - Zhou, W. PY - 2018 DA - 2018// TI - MiR-98 modulates macrophage polarization and suppresses the effects of tumor-associated macrophages on promoting invasion and epithelial-mesenchymal transition of hepatocellular carcinoma JO - Cancer Cell Int VL - 18 UR - https://doi.org/10.1186/s12935-018-0590-3 DO - 10.1186/s12935-018-0590-3 ID - Li2018 ER - TY - JOUR AU - Li, L. AU - Sun, P. AU - Zhang, C. AU - Li, Z. AU - Zhou, W. PY - 2018 DA - 2018// TI - MiR-98 suppresses the effects of tumor-associated macrophages on promoting migration and invasion of hepatocellular carcinoma cells by regulating IL-10 JO - Biochimie. VL - 150 UR - https://doi.org/10.1016/j.biochi.2018.04.016 DO - 10.1016/j.biochi.2018.04.016 ID - Li2018 ER - TY - JOUR AU - Das, M. AU - Zhu, C. AU - Kuchroo, V. PY - 2017 DA - 2017// TI - Tim-3 and its role in regulating anti-tumor immunity JO - Immunol Rev VL - 276 UR - https://doi.org/10.1111/imr.12520 DO - 10.1111/imr.12520 ID - Das2017 ER - TY - JOUR AU - Mujib, S. AU - Jones, R. AU - Lo, C. AU - Aidarus, N. AU - Clayton, K. AU - Sakhdari, A. PY - 2012 DA - 2012// TI - Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway JO - J Immunol (Baltimore, Md : 1950) VL - 188 UR - https://doi.org/10.4049/jimmunol.1102609 DO - 10.4049/jimmunol.1102609 ID - Mujib2012 ER - TY - STD TI - W Zhang, Y Liu, Z Yan, H Yang, W Sun, Y Yao, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. Journal for immunotherapy of cancer. 2020;8(1). ID - ref90 ER - TY - JOUR AU - Xie, K. AU - Xu, L. AU - Wu, H. AU - Liao, H. AU - Luo, L. AU - Liao, M. PY - 2018 DA - 2018// TI - OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis JO - Oncoimmunology. VL - 7 UR - https://doi.org/10.1080/2162402X.2017.1404214 DO - 10.1080/2162402X.2017.1404214 ID - Xie2018 ER - TY - JOUR AU - Gefen, T. AU - Castro, I. AU - Muharemagic, D. AU - Puplampu-Dove, Y. AU - Patel, S. AU - Gilboa, E. PY - 2017 DA - 2017// TI - A TIM-3 oligonucleotide Aptamer enhances T cell functions and potentiates tumor immunity in mice JO - Mol Ther VL - 25 UR - https://doi.org/10.1016/j.ymthe.2017.06.023 DO - 10.1016/j.ymthe.2017.06.023 ID - Gefen2017 ER - TY - JOUR AU - Hervas-Stubbs, S. AU - Soldevilla, M. AU - Villanueva, H. AU - Mancheño, U. AU - Bendandi, M. AU - Pastor, F. PY - 2016 DA - 2016// TI - Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.6608 DO - 10.18632/oncotarget.6608 ID - Hervas-Stubbs2016 ER - TY - JOUR AU - Prodeus, A. AU - Abdul-Wahid, A. AU - Fischer, N. AU - Huang, E. AU - Cydzik, M. AU - Gariépy, J. PY - 2015 DA - 2015// TI - Targeting the PD-1/PD-L1 immune evasion Axis with DNA Aptamers as a novel therapeutic strategy for the treatment of disseminated cancers JO - Mol Ther Nucleic acids VL - 4 UR - https://doi.org/10.1038/mtna.2015.11 DO - 10.1038/mtna.2015.11 ID - Prodeus2015 ER - TY - JOUR AU - Salmon, H. AU - Remark, R. AU - Gnjatic, S. AU - Merad, M. PY - 2019 DA - 2019// TI - Host tissue determinants of tumour immunity JO - Nat Rev Cancer VL - 19 ID - Salmon2019 ER - TY - JOUR AU - Reina-Campos, M. AU - Moscat, J. AU - Diaz-Meco, M. PY - 2017 DA - 2017// TI - Metabolism shapes the tumor microenvironment JO - Curr Opin Cell Biol VL - 48 UR - https://doi.org/10.1016/j.ceb.2017.05.006 DO - 10.1016/j.ceb.2017.05.006 ID - Reina-Campos2017 ER - TY - JOUR AU - Riera-Domingo, C. AU - Audigé, A. AU - Granja, S. AU - Cheng, W. AU - Ho, P. AU - Baltazar, F. PY - 2020 DA - 2020// TI - Immunity, hypoxia, and metabolism-the Ménage à Trois of Cancer: implications for immunotherapy JO - Physiol Rev VL - 100 UR - https://doi.org/10.1152/physrev.00018.2019 DO - 10.1152/physrev.00018.2019 ID - Riera-Domingo2020 ER - TY - STD TI - MZ Norman, M Hasmim, A Lequeux, M Xiao, C Duhem, S Chouaib, et al. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells. 2019;8(9). ID - ref98 ER - TY - JOUR AU - Zhang, J. AU - Zhang, Q. AU - Lou, Y. AU - Fu, Q. AU - Chen, Q. AU - Wei, T. PY - 2018 DA - 2018// TI - Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment JO - Hepatology (Baltimore, Md) VL - 67 UR - https://doi.org/10.1002/hep.29681 DO - 10.1002/hep.29681 ID - Zhang2018 ER - TY - JOUR AU - Noman, M. AU - Desantis, G. AU - Janji, B. AU - Hasmim, M. AU - Karray, S. AU - Dessen, P. PY - 2014 DA - 2014// TI - PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation JO - J Exp Med VL - 211 UR - https://doi.org/10.1084/jem.20131916 DO - 10.1084/jem.20131916 ID - Noman2014 ER - TY - JOUR AU - Barsoum, I. AU - Smallwood, C. AU - Siemens, D. AU - Graham, C. PY - 2014 DA - 2014// TI - A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-0992 DO - 10.1158/0008-5472.CAN-13-0992 ID - Barsoum2014 ER - TY - JOUR AU - Chen, J. AU - Chen, J. AU - Huang, J. AU - Li, Z. AU - Gong, Y. AU - Zou, B. PY - 2019 DA - 2019// TI - HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway JO - Aging. VL - 11 UR - https://doi.org/10.18632/aging.102488 DO - 10.18632/aging.102488 ID - Chen2019 ER - TY - JOUR AU - Gropper, Y. AU - Feferman, T. AU - Shalit, T. AU - Salame, T. AU - Porat, Z. AU - Shakhar, G. PY - 2017 DA - 2017// TI - Culturing CTLs under hypoxic conditions enhances their cytolysis and improves their anti-tumor function JO - Cell Rep VL - 20 UR - https://doi.org/10.1016/j.celrep.2017.08.071 DO - 10.1016/j.celrep.2017.08.071 ID - Gropper2017 ER - TY - JOUR AU - Sormendi, S. AU - Wielockx, B. PY - 2018 DA - 2018// TI - Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.00040 DO - 10.3389/fimmu.2018.00040 ID - Sormendi2018 ER - TY - STD TI - Chan MC, Holt-Martyn JP, Schofield CJ, Ratcliffe PJ. Pharmacological targeting of the HIF hydroxylases--a new field in medicine development. Mol Asp Med. 2016:54–75. ID - ref105 ER - TY - JOUR AU - Wu, L. AU - Zhang, X. AU - Zheng, L. AU - Zhao, H. AU - Yan, G. AU - Zhang, Q. PY - 2020 DA - 2020// TI - RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and Hepatocarcinogenesis JO - Cancer Immunol Res VL - 8 UR - https://doi.org/10.1158/2326-6066.CIR-19-0261 DO - 10.1158/2326-6066.CIR-19-0261 ID - Wu2020 ER - TY - JOUR AU - Tian, X. AU - Wu, Y. AU - Yang, Y. AU - Wang, J. AU - Niu, M. AU - Gao, S. PY - 2020 DA - 2020// TI - Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling JO - Mol Oncol VL - 14 UR - https://doi.org/10.1002/1878-0261.12606 DO - 10.1002/1878-0261.12606 ID - Tian2020 ER - TY - JOUR AU - Yang, Y. AU - Ye, Y. AU - Chen, Y. AU - Zhao, J. AU - Gao, C. AU - Han, H. PY - 2018 DA - 2018// TI - Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors JO - Cell Death Dis VL - 9 UR - https://doi.org/10.1038/s41419-018-0818-0 DO - 10.1038/s41419-018-0818-0 ID - Yang2018 ER - TY - JOUR AU - Li, Q. AU - Ma, L. AU - Shen, S. AU - Guo, Y. AU - Cao, Q. AU - Cai, X. PY - 2019 DA - 2019// TI - Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-019-1271-3 DO - 10.1186/s13046-019-1271-3 ID - Li2019 ER - TY - JOUR AU - Yang, F. AU - Wei, Y. AU - Han, D. AU - Li, Y. AU - Shi, S. AU - Jiao, D. PY - 2020 DA - 2020// TI - Interaction with CD68 and regulation of GAS6 expression by Endosialin in fibroblasts drives recruitment and polarization of macrophages in hepatocellular carcinoma JO - Cancer Res VL - 80 UR - https://doi.org/10.1158/0008-5472.CAN-19-2691 DO - 10.1158/0008-5472.CAN-19-2691 ID - Yang2020 ER - TY - JOUR AU - Shiau, D. J. AU - Kuo, W. T. AU - Davuluri, G. V. N. AU - Shieh, C. C. AU - Tsai, P. J. AU - Chen, C. C. PY - 2020 DA - 2020// TI - Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis JO - Sci Rep VL - 10 UR - https://doi.org/10.1038/s41598-020-70137-4 DO - 10.1038/s41598-020-70137-4 ID - Shiau2020 ER - TY - JOUR AU - Zhao, X. AU - Wang, X. AU - You, Y. AU - Wen, D. AU - Feng, Z. AU - Zhou, Y. PY - 2020 DA - 2020// TI - Nogo-B fosters HCC progression by enhancing yap/Taz-mediated tumor-associated macrophages M2 polarization JO - Exp Cell Res VL - 391 UR - https://doi.org/10.1016/j.yexcr.2020.111979 DO - 10.1016/j.yexcr.2020.111979 ID - Zhao2020 ER - TY - JOUR AU - Cassetta, L. AU - Pollard, J. PY - 2018 DA - 2018// TI - Targeting macrophages: therapeutic approaches in cancer JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2018.169 DO - 10.1038/nrd.2018.169 ID - Cassetta2018 ER -